Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Opts For Education Over Registries in Proposed Opioids REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Registries could have adverse impact on patient access, notes Bob Rappaport, director of CDER's Division of Anesthesia and Analgesia Products.

You may also be interested in...



Private Grünenthal Aims For Leadership In Pain

Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.

Private Grünenthal Aims For Leadership In Pain

Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.

FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training

Prior training programs have been much smaller in scope, OND Director John Jenkins points out.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel